Although data is limited, and studies are still in early stages, still, early research on the Omicron variation of COVID-19 shows that there may be an increased risk of reinfection with this variant, meaning that those who have previously been infected with COVID-19 may be more readily reinfected, according to WHO.
Vaccines, notably those against the major circulating form, Delta, are crucial in decreasing severe illness and mortality, according to the WHO.
WHO is collaborating with technical partners to determine the impact of this variation on current countermeasures, such as vaccinations.
Vaccines, notably those against the major circulating form, Delta, are crucial in lowering severe illness and mortality.
As we’ve observed with previous variations, commonly used PCR tests continue to identify infection, even infection with Omicron.
Other types of testing, such as quick antigen detection tests, are being studied to see whether there is any impact.
According to the WHO, researchers in South Africa and around the world are conducting studies to better understand many aspects of Omicron and will continue to share the findings of these studies as they become available.